AbbVie's Study of Weight-Loss Drug Outperforms Placebo

MT Newswires Live03-09

AbbVie (ABBV) said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.

The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.

AbbVie also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.

These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.

Price: 229.13, Change: -0.95, Percent Change: -0.41

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618808624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618808624","market":"sh","top_or_hot":-1,"title":"AbbVie's Study of Weight-Loss Drug Outperforms Placebo","media":"MT Newswires Live","content":"<html><body><p> AbbVie (ABBV) said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.</p><p>The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.</p><p>AbbVie also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.</p><p>These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.</p><p>Price: 229.13, Change: -0.95, Percent Change: -0.41</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie's Study of Weight-Loss Drug Outperforms Placebo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie's Study of Weight-Loss Drug Outperforms Placebo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AbbVie (ABBV) said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.</p><p>The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.</p><p>AbbVie also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.</p><p>These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.</p><p>Price: 229.13, Change: -0.95, Percent Change: -0.41</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618808624","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618808624","pubTimestamp":1773064213,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbbVie  said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.AbbVie also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.Price: 229.13, Change: -0.95, Percent Change: -0.41","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司"},"translate_title":"艾伯维减肥药研究优于安慰剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5},"content_text":"AbbVie (ABBV) said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.AbbVie also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.Price: 229.13, Change: -0.95, Percent Change: -0.41","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618808624","isCrawlerRequest":true}